Public Health Meaningful Use Criteria

Select textsizemediumlargelarger

Meaningful Use Stage 2 – Cancer Reporting FAQs

  1. Who is required to report cancer information to the New Jersey State Cancer Registry (NJSCR) as part of Meaningful Use Stage 2 (MU2)?

  2. What do providers have to do to meet cancer reporting objectives?

  3. How long do providers have to respond to NJSCR’s requests during the onboarding process?

  4. Is the NJSCR able to certify that a Provider achieved Cancer Meaningful Use or met the public health objective for cancer reporting?

  5. Will the NJSCR be prepared to accept electronically transmitted cancer case information from Providers in the Clinical Document Architecture(CDA) format, as required by MU2 in 2014?

  6. When will the NJSCR be prepared to begin testing MU2 data transmissions?

  7. What can Providers do until onboarding begins?

  8. What method of transmission does NJSCR support?

  9. How often will NJSCR accept electronic transmissions?

  10. Would an EHR vendor be able to obtain one set of credentials to connect, or is each provider organization required to have a distinct login?

  11. Does NJSCR accept data in the format set forth by the Implementation Guide for Healthcare Providers Reporting to Central Cancer Registries, Release 2.0, August 2012, HL7 CDA, as outlined by the Office of the National Coordinator for Health Information Technology (ONC) Final Rule on MU?

  12. Does NJSCR plan to declare its readiness by sharing information with Centers for Medicare and Medicaid Services(CMS) and submitting this information as part of CMS’ central repository?

  13. Will NJSCR require Providers to “register intent” for their chosen reporting period?

  14. What can Providers expect after registration is complete?

  15. What are some of the tools available to Providers as part of MU2 activities?

  16. Who can I contact for more information?

  17. How can I stay abreast of MU2 updates from the NJSCR?

  1. Who is required to report cancer information to the New Jersey State Cancer Registry (NJSCR) as part of Meaningful Use Stage 2 (MU2)?

    Cancer reporting by ambulatory care facilities and physicians [also referred to as Eligible Professionals (EP) or Providers] as part of MU2 is voluntary.  However, New Jersey regulations require the reporting of all newly diagnosed cancer cases by hospitals, physicians, ambulatory care facilities, radiation treatment facilities and private laboratories; and, submitting data electronically is strongly encouraged (refer to Cancer Registry Regulation).

  2. What do providers have to do to meet cancer reporting objectives?

    Providers can meet cancer reporting objectives by first registering their intent to submit cancer data for MU2 (Meaningful Use Stage 2 Registration for the New Jersey State Cancer Registry)  AND doing ONE of the following:

    • Achieving ongoing submission of data during your EHR reporting period, or
    • Being engaged with the NJSCR in testing and validation of data, or
    • Waiting for an invitation from the NJSCR to begin testing and validation.

  3. How long do providers have to respond to NJSCR’s requests during the onboarding process?

    Providers have 30 days to respond to NJSCR requests.  Failure to respond within 30 days on two (2) separate occasions will not meet the cancer reporting objective.

  4. Is the NJSCR able to certify that a Provider achieved Cancer Meaningful Use or met the public health objective for cancer reporting?

    Meaningful Use is a mandate of the Centers for Medicare and Medicaid Services (CMS); therefore NJSCR is not a designated certifying authority. NJSCR can only acknowledge that a Provider submitted ongoing cancer information to the NJSCR during the Provider’s EHR reporting period.

  5. Will the NJSCR be prepared to accept electronically transmitted cancer case information from Providers in the Clinical Document Architecture(CDA) format, as required by MU2 in 2014?

    The NJSCR is actively working with the Rutgers Cancer Institute of New Jersey and the vendor supporting core registry functions to prepare to receive electronically transmitted cancer cases information. Please check this website periodically for an updated MU 2 workflow. Providers are encouraged to begin the submission process by registering their intent with the NJSCR - Meaningful Use Stage 2 Registration for the New Jersey State Cancer Registry.

  6. When will the NJSCR be prepared to begin testing MU2 data transmissions?

    The NJSCR may begin testing MU2 data transmissions in the Summer of 2014 and will contact Providers who have registered to begin the onboarding process.  You may also visit our Meaningful Use website periodically for up-to-date information.

  7. What can Providers do until onboarding begins?

    Providers may prepare to validate their MU2 transmission data by using the validation tool developed by the National Institute of Standards and Technology (NIST). The validation tool contains rules for Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries (and all associated and referenced specifications) as referenced in Meaningful Use Stage 2 guidelines. More information about the validation tool can be found at Meaningful Use Cancer Registry Report Validation.

  8. What method of transmission does NJSCR support?

    The method of transmission has not been determined.  The NJSCR is working with its database administrators and information technology experts to determine the most feasible, efficient, and secure method of transmission that will best meet the needs of both the Provider and the NJSCR.

  9. How often will NJSCR accept electronic transmissions?

    Although Providers are required to report all newly diagnosed cancer cases within 6 months of diagnosis as part of the cancer reporting statute, the NJSCR may accept transmissions more frequently during the onboarding process to facilitate successful ongoing MU2 submission of cancer case information for the Provider’s entire EHR reporting period.  After the initial onboarding process, Providers may be able to submit MU2 data monthly or quarterly as determined by the NJSCR, taking into account patient/record volume and available resources.

  10. Would an EHR vendor be able to obtain one set of credentials to connect, or is each provider organization required to have a distinct login?

    This has not yet been determined. However, the NJSCR will require that Providers be identified within each transmission in order to document the source of the record (e.g. the individual providers and/or the group practice). This information will also be important for ongoing monitoring and quality assurance.

  11. Does NJSCR accept data in the format set forth by the Implementation Guide for Healthcare Providers Reporting to Central Cancer Registries, Release 2.0, August 2012, HL7 CDA, as outlined by the Office of the National Coordinator for Health Information Technology (ONC) Final Rule on MU?

    Yes.  NJSCR encourages Providers to submit MU2 data in the format described in the Implementation Guide for Ambulatory Healthcare Provider Reporting to Central Cancer Registries.  If your EHR is not a certified electronic health record technology (CEHRT) but you would like to submit electronic cancer data to NJSCR, please visit Cancer Reporting for physicians, ambulatory care centers, radiation treatment facilities as other formats and data transmission options are available to providers to help meet their state reporting obligations.

  12. Does NJSCR plan to declare its readiness by sharing information with CMS and submitting this information as part of CMS’ central repository?

    NJSCR will declare its readiness as part of the CMS central repository when it becomes available in January 2014 (see Meaningful Use Stage 2 Public Health Agency Readiness).

  13. Will NJSCR require Providers to “register intent” for their chosen reporting period?

    Yes.  Providers must register their intent to submit MU2 data before the onboarding process can begin.  The information provided through the registration process will help to facilitate the onboarding process. To register your intent, go to Meaningful Use Stage 2 Registration for the New Jersey State Cancer Registry.  After registration, Providers will receive an email acknowledging registration.  The email should be retained as documentation that you have successfully registered your intent.

  14. What can Providers expect after registration is complete?

    The NJSCR will contact registered Providers to begin the onboarding process, which will include sending data for testing and correcting data that fails NJSCR validity protocols.  The onboarding process will be an iterative process and may require several test cycles before the data can be validated.  The onboarding process will end when data that have passed the validation process are submitted on an ongoing basis during the Provider’s EHR reporting period.

  15. What are some of the tools available to Providers as part of MU2 activities?

    One tool that can be useful to Providers as they prepare to submit MU2 data to NJSCR is the validation tool developed by the National Institute of Standards and Technology (NIST).  The validation tool contains rules for IG for Ambulatory Healthcare Provider Reporting to Central Cancer Registries (and all associated and referenced specifications) as referenced in MU2 guidelines.  More information about Meaningful Use Cancer Registry Report Validation.

  16. Who can I contact for more information?

    If you would like more information or have other questions, please email the NJSCR MU2 coordinator(s) at NJSCR.MU2@doh.state.nj.us.  Please be sure to include your full name and contact information.

  17. How can I stay abreast of MU2 updates from the NJSCR?

    You can stay abreast of NJSCR MU2 activities by visiting our MU website periodically and/or subscribing to our mailing list. You can subscribe to our mailing list during the registration process. All correspondence with regard to NJSCR MU2 activities will be sent from NJSCR-MU2PROVIDERS@LISTS.UMDNJ.EDU.